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Coronavirus disease 2019 (COVID-19) remains a major health challenge globally. Previous
studies have suggested that changes in the glycosylation of IgG are closely associated with
the severity of COVID-19. This study aimed to compare the profiles of IgG N-glycome
between COVID-19 patients and healthy controls. A case-control study was conducted, in
which 104 COVID-19 patients and 104 age- and sex-matched healthy individuals were
recruited. Serum IgG N-glycome composition was analyzed by hydrophilic interaction
liquid chromatography with the ultra-high-performance liquid chromatography
(HILIC-UPLC) approach. COVID-19 patients have a decreased level of IgG fucosylation,
which upregulates antibody-dependent cell cytotoxicity (ADCC) in acute immune
responses. In severe cases, a low level of IgG sialylation contributes to the ADCC-
regulated enhancement of inflammatory cytokines. The decreases in sialylation and
galactosylation play a role in COVID-19 pathogenesis via the activation of the lectin-
initiated alternative complement pathway. IgG N-glycosylation underlines the complex
clinical phenotypes of SARS-CoV-2 infection.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2), remains a global health challenge. COVID-19 has resulted in more than 194.0
million infections and 4.1 million deaths as of July 26, 2021 (1). SARS-CoV-2 is a positive-sense
single-stranded RNA virus with four structural proteins: small envelope (E), matrix (M),
nucleocapsid (N), and spike (S) (2). The transmembrane S protein is extensively glycosylated
with a total of 22 N-linked glycan sequons per protomer which mediate infectivity and immune
escape (3, 4). While understanding that the glycan structures of SARS-CoV-2 potentially assist
vaccines design, antibody therapeutics, screening of small-molecule drugs and their targets (5–7),
Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 7485661
Edited by:
Sheng-ce Tao,











†These authors have contributed
equally to this work
Specialty section:
This article was submitted to
Viral Immunology,
a section of the journal
Frontiers in Immunology
Received: 29 July 2021
Accepted: 06 September 2021
Published: 23 September 2021
Citation:
Hou H, Yang H, Liu P,
Huang C, Wang M, Li Y,
Zhu M, Wang J, Xu Y, Wang Y,
Ma Q, Li D, Liao P and Wang W
(2021) Profile of Immunoglobulin
G N-Glycome in COVID-19




published: 23 September 2021
doi: 10.3389/fimmu.2021.748566
and recognition of the human immunoglobulin G (IgG) glycome
hold the similar relevance to investigate the susceptibility and
complicated clinical phenotypes of the SARS-CoV-2 infection.
As a set of glycoproteins, IgG is attached with two N-linked
glycans at asparagine 297 sites of the fragment crystallizable (Fc)
segments in heavy chains (8, 9). These glycans modulate the
inflammatory properties of IgG by changing the affinity for
specific receptors and lectins (10), which are involved in the
development of inflammatory diseases (11–16). Progression of
dengue virus (DENV) infection attributed to antibody-dependent
enhancement (ADE) is proved to be regulated by specific IgG
glycosylation (17). However, there is limited knowledge on IgG
glycosylation that is associated with SARS-CoV-2 infection.
Recently, the levels of bisecting N-acetylglucosamine (GlcNAc)
and galactosylation of IgG were reported to be negatively
correlated to the severity of the European COVID-19 patients
(18). Meanwhile, IgG afucosylation was observed to be positively
correlated with the severity of COVID-19 (19). Moreover, a study
showed that IgG against SARS-CoV-2 S protein is characterized
by afucosylation, whereas IgG against N protein has a higher level
of fucosylation (20). These findings support the notion that
changes in IgG glycome composition are closely related to the
loss of the immunosuppressive function and contribute to the
immune-mediated pathologies of SARS-CoV-2 infection (18).
We aimed to profile the IgG N-glycome in COVID-19 patients
by an age- and sex-matched case-control study.
MATERIALS AND METHODS
Study Participants
We randomly enrolled 104 COVID-19 patients who were
hospitalized in Chongqing Public Health Medical Center from
January 24 to May 6, 2020. The inclusion criteria are as follows:
(1) diagnosed in accordance with the eighth edition of the
Diagnosis and Treatment Plan for COVID-19 issued by the
National Health Commission of China both male and female
patients with COVID-19; (2) definitive diagnosis using
polymerase chain reaction (PCR) test; (3) did not receive
vaccines in the preceding 6 months; and (4) not enrolled in
other clinical trials. The exclusion criteria are as follows:
(1) patients with other viral diseases; (2) patients who have been
undergoing chemotherapy for the past month; (3) patients with
severe diseases, such as coronary heart disease, stroke, and cancers;
and (4) patients with autoimmune diseases. All patients were
recruited at the first week of hospitalization. As controls, 104 age-
and sex-matched healthy participants were enrolled from a local
community-based cohort. The Ethical Committee of Chongqing
General Hospital approved this study (No. S2020-021-01).
Informed consent was obtained from each study participant.
Analysis of Immunoglobulin G Glycans
Isolation of IgG and release of N-glycans were performed as
described previously (21, 22). Briefly, the frozen sera were
thawed, and were centrifugated at 80 g for 10 min. Dilute the
samples with 1× phosphate-buffered saline (PBS, pH = 7.4) by
1:7 (v/v). The samples were then transferred to the protein G
monolithic plate, for IgG binding and cleaning, followed by PBS
washing as previously reported. IgG samples were eluted with
1 ml of 0.1 M formic acid and filtered into the collection plate by
a vacuum pump. And, 170 µl of 1 M ammonium bicarbonate was
added to each plate with shock blending.
Isolated IgG samples were denaturized with 20 µl of 2% sodium
dodecyl sulfonate (v/v) in a 65°C oven for 10 min. Then, 10 µl of
4% IGEPAL was added and incubated in a shaking incubator for 5
min. After the samples were regulated by (30 ul) 0.1 mol/L NaOH
and 20 µl of 5 × PBS to a pH of 8.0 with shock blending, then 4 µl
of PNGase F enzyme were added. And the samples were incubated
in a 37°C water bath for N-Glycan release.
The released N-glycans were labeled with 35 µl of 2-
aminobenzamide(2-AB) mixed solution reagent, and transferred
into an oscillator for about 10 min, then transferred into an oven
at 65°C for 3 h. The 2-AB labeled glycans were purified by 100%
acetonitrile, and eluted with 100 µl of ultra-pure water. The 2-AB
labeled glycans were transferred into an oven to dry at 60°C for
3.5 h, and then saved at -80°C until further measurement.
N-glycan samples were dissolved with a mixture of 100%
acetonitrile and ultra-pure water at a 2:1 ratio (v/v). Then, it was
centrifuged at 134 g for 5 min and 20 µl of the labeled N-glycans
was loaded into the UPLC instruments. The glycans were
analyzed with hydrophilic interaction liquid chromatography
(HILIC) on a UPLC instrument (Walters Corporation, Milford,
MA) (22, 23). A total of 24 chromatographic glycan peaks (GPs
1–24) were identified as initial glycans. Each glycan was
quantified as relative values of the GP to total GPs. The glycan
structure in each peak was matched as previously reported (22).
We further calculated the derived glycans using the measurement
data of the initial GPs, which consist of sialylation trait, bisecting
GlcNAc trait, galactosylation trait, and fucosylation trait (11).
Statistical analyses were performed on each glycan, and also on
the summary features of the IgG glycome composition, i.e., G1:
glycans with one galactose, G2: glycans with two galactoses, G0:
glycans without galactose, S: sialic acid, F: fucose, and B:
bisecting GlcNAc.
Statistical Analysis
Normal distribution of all analysis results was checked using the
Kolmogorov-Smirnov test. Continuous variables underlying the
abnormal distribution were represented as the medians
(interquartile ranges). The difference of continuous variables
between two groups was tested using the Wilcoxon rank-sum
test. Statistical analyses were carried out with the SPSS software,
version 25.0 (IBM, New York, USA). All reported P-values were
two-sided, and a P < 0.05 was considered statistically significant.
RESULTS
Characteristics of Study Participants
In this case-control study, we recruited 104 COVID-19 patients (50
men/54 women, mean age 44.81 years) from Chongqing Public
Health Medical Center, Chongqing, China. Simultaneously, 104
Hou et al. IgG Profile of COVID-19 Patients
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age- and sex-matched healthy participants were enrolled from a
local community-based cohort. Of the 104 COVID-19 patients, 18
were severe cases (with respiratory rate ≥ 30 times/min, oxygen
saturation ≤ 93% on ambient air), and 86 were mild cases. The
characteristics of the study participants are shown in Table 1.
The Immunoglobulin G Glycome
Composition in Participants
A total of 24 initial glycan peaks (GP1–GP24) were obtained
from all the chromatograms of UPLC. As shown in Table S1, 10
GPs (GP1, GP3, GP5, GP11, GP13, GP17, GP20, GP21, GP22,
and GP23) were significantly higher in COVID-19 patients than
that of the controls (Table S2), whereas another 12 GPs (GP2,
GP4, GP6, GP8, GP9, GP10, GP12, GP14, GP16, GP18, GP19,
and GP24) were lower in COVID-19 patients. We further
calculated the derived glycans traits using the measurement
data of the initial GPs, which consist of sialylation, bisecting
GlcNAc, galactosylation trait, and fucosylation traits (11). As
listed in Table S2, 39 of 54 derived glycans were differential
between the COVID-19 patients and the controls.
Fucosylation
Afucosylation upregulates the capability of IgG to trigger
antibody-dependent cell cytotoxicity (ADCC) and leads to the
enhancement of inflammatory cytokines produced by monocytes.
An increase in IgG afucosylation has been observed among severe
COVID-19 patients in earlier studies involving Caucasian
populations (18, 20). As shown in Figure 1, 14 fucosylated
glycans (GP4, GP6, GP8, GP9, GP10, GP14, GP16, GP18, GP19,
Fn total, FG2n total/G2n, Fn, FG1n/G1n, and FG2n/G2n) were
significantly lower in the COVID-19 group when compared to
the controls. The percentage of glycans with fucose was 82.54% in
the COVID-19 cases, which was significantly lower than that in
the control group (95.64%) (Table 2).
However, the levels of fucosylated IgG in the severe COVID-
19 cases (87.94%) were significantly higher than those in the mild
cases (85.54%), which might be attributed to the heterogeneity of
age between severe and mild cases (Table 3). Furthermore, we
analyzed the core fucosylation of IgG in the severe COVID-19
cases compared to the mild patients. As listed in Table S3, no
differences in core fucosylated moieties were identified between
the severe and mild cases.






Sex (men/women) 50/54 50/54 –
Age 44.81 ± 13.96 44.62 ± 11.629 0.918
WBC 5.31 (4.23–6.73) 6.02 (4.89–7.11) 0.005
RBC 4.35 (3.95–4.65) 4.67 (4.25–5.04) <0.001
PLT 201.00 (266.00–272.00) 262.00 (222.00–296.00) <0.001
ALT 22.00 (17.00–39.00) 24.00 (18.00–33.00) 0.357
AST 20.00 (17.00–27.00) 21.00 (18.00–26.00) 0.518
Cr 64.55 (57.60–74.18) 66.00 (57.00–74.00) 0.921
UA 307.77 ± 86.06 305.22 ± 74.82 0.588
FBG 5.72 (5.32–7.06) 5.67 (5.32–6.21) 0.118
Hypertension 6 (5.77%) 0 –
Hyperlipidemia 2 (1.92%) 0 –
Hyperuricemia 1 (0.96%) 0 –
Diabetes 11 (10.58%) 0 –
ALT, alanine aminotransferase; AST, aspartate aminotransferase; Cr, serum creatinine;
FBG, fasting blood glucose; PLT, platelet; RBC, red blood cell; UA, serum uric acid; WBC,
white blood cell.
FIGURE 1 | Fucosylation on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan
peak; S, Sialic acid; ↑, the glycan in COVID-19 group is significantly higher than that in the controls; ↓, the glycan in COVID-19 group is significantly lower than that in
the controls.
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Sialylation
IgG sialylation, also known as N-acetylneuraminic acid (Neu5Ac)-
linked IgG, regulates pro-inflammation and anti-inflammation
balance. The decrease in IgG sialylation upregulates the antibody-
dependent cell cytotoxicity (ADCC) pathway and is linked to
activation of the lectin-initiated alternative complement pathway
(24). In this study, 11 sialylated glycans (GP17, GP21, GP22, GP23,
FGS/(FG+FGS), FGS/(F+FG+FGS), FG2S1/(FG2+FG2S1+FG2S2),
FG2S2/(FG2+FG2S1+FG2S2), FBG2S1/(FBG2+FBG2S1+
FBG2S2), FtotalS1/FtotalS2, and FBS1/FBS2) were higher in the
COVID-19 patients (Figure 2). In total, a higher abundance of
sialylated glycans was identified in the COVID-19 group (29.68%)
than that in the controls (20.60%) (Table 2). Meanwhile, a lower
level of total sialylated glycans was observed in the severe patients
(18.93%) than that in the mild cases (26.09%) (Table 3).
Bisecting GlcNAc
With regard to bisecting GlcNAc, the decrease of GP6, GP10,
GP19, GP24, FBStotal/FStotal, FBS2/FS2, and FBS2/(FS2+FBS2)
were identified in the COVID-19 cases (Figure 3). The
percentage of glycans with bisecting GlcNAc was significantly
lower in the COVID-19 cases (14.30%) than that in the controls
(15.39%) (Table 2). Nevertheless, no difference in the total
bisecting N-GlcNAc was found between the severe and mild
cases (13.22% vs. 15.38%) (Table 3).
TABLE 2 | Relative abundance (%) of the main IgG glycome features in COVID-19 patients and the healthy controls.
Summary glycans COVID-19 patients (n = 104) Controls (n = 104) Z P
Fucosylation 82.54 (72.36–87.21) 95.64 (94.12–96.69) 10.874 <0.001
Bisecting GlcNAc 14.30 (12.57–15.66) 15.39 (13.48–17.08) 2.398 0.016
Galactosylation 76.13 (67.14–83.02) 69.21 (63.41–72.93) 4.668 <0.001
Sialylation 29.68 (21.75–39.29) 20.60 (17.48–23.82) 6.296 <0.001
GlcNAc, N-acetylglucosamine.
TABLE 3 | Relative abundance (%) of the main IgG glycome features in severe and mild COVID-19 patients.
Summary glycans Severe patients (n = 18) Mild patients (n = 86) Z P
Fucosylation 87.94 (82.05–92.63) 85.54 (82.22–90.22) 3.342 0.001
Bisecting GlcNAc 13.22 (11.81–15.68) 15.38 (13.48–17.08) 1.413 0.158
Galactosylation 58.32 (53.57–62.47) 74.07 (64.54–75.71) 4.734 <0.001
Sialylation 18.93 (8.73–24.81) 26.09 (17.79–32.33) 3.746 <0.001
GlcNAc, N-acetylglucosamine.
FIGURE 2 | Sialylation on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan peak;
S, Sialic acid; ↑, the glycan in COVID-19 group is significantly higher than that in the controls; ↓, the glycan in COVID-19 group is significantly lower than that in the controls.
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Galactosylation
Agalactosylated IgG is recognized to be associated with the activation
of the lectin-initiated complement pathway in the development of
inflammatory diseases (11). As shown in Figure 4, the level of
galactosylated glycans was significantly higher in the COVID-19
patients (76.13%) when compared to the controls (69.21%) (Table 2).
Furthermore, a decrease in galactosylated IgG was identified in the
severe COVID-19 cases (58.32%) than that in the mild cases
(74.07%) (Table 3), meaning that agalactosylated IgG plays a role
in the inflammatory process among severe COVID-19 cases.
Time Trend of Immunoglobulin G
Glycosylation Profiles
A previous follow-up study demonstrated that the IgG level increases
from the first week of symptomonset to the fifth week, thenmaintains
a stable level until the seventh week. In order to explore if the IgG
glycosylation profile follows a certain trajectory, we followed-up 23
patients for 4 weeks, and recorded the IgGN-glycans in the first week,
two to three weeks, and the fourth week after their clinical diagnoses.
As shown in Table S4, the levels of the 24 initial glycans detected by
HILIC-UPLC were not significantly different between the three
follow-up durations, indicating that the IgG glycosylation profile is
relatively stable after the clinical symptom onset.
Age- and Sex-Differences in
Immunoglobulin G Glycosylation
The relative proportions (%) of the main IgG glycome features
were compared between the COVID-19 patients who were
divided into three tertile groups. As shown in Table S5, there
were no significant differences between the three groups.
Meanwhile, no differences were observed between men and
women (Table S6).
DISCUSSION
Our findings reaffirm that SARS-CoV-2 infection is associated with
the absence of the fucosylation of IgG, which triggers ADCC-
regulated acute immune responses. Compared to the mild cases, the
severe ones might have a lower level of IgG sialylation, which leads
to the ADCC-regulated enhancement of inflammatory cytokines
and activation of the lectin-initiated alternative complement
pathway. In severe cases, the decreases in sialylation and
galactosylation might also play a role in the activation of the
lectin-initiated alternative complement pathway (Figure 5).
Cytokine storm resulting from the overactivation of the
innate immune system is one of the key features of severe
COVID-19 but significantly varies between individuals (25).
Besides, increased levels of pro-inflammatory cytokines are not
observed in all severe patients (26). Inter-patient differences in
the IgG glycome profiles are apparent and reflect both genetic
and environmental determinants (27), which hypothetically
contribute to the abnormal expression of glycosyltransferase
and glycosidase in plasma cells or B cells, resulting in the
different susceptibility of the SARS-CoV-2 infection and
severity of the COVID-19. These changes in the IgG glycome
FIGURE 3 | Bisecting GlcNAc on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan peak; S,
Sialic acid; ↑, the glycan in COVID-19 group is significantly higher than that in the controls; ↓, the glycan in COVID-19 group is significantly lower than that in the controls.
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may make it possible to switch between anti-inflammatory and
pro-inflammatory effects upon antigenic challenge (28).
Increased cytokines and chemokines activated peripheral
immune cells such as neutrophils and monocytes, penetrate
lung tissue, and cause impairments on target cells (29).
Consequently, IgG glycosylation might play a cascading role in
the progression of COVID-19 pathogenesis.
Here, a significant decrease in the fucosylation of IgG was
identified in the COVID-19 cases compared to the healthy
controls. This finding is partly consistent with an earlier study
(20), in which a decrease in fucosylated IgG against S protein and
an increase in fucosylated IgG against N protein were observed
among severe COVID-19 patients compared to the mild ones.
However, the underlying mechanism that induces these
differences was not elucidated. In our study, the total IgGs
against multiple antigenic epitopes were examined, including
both anti-S and anti-N IgGs. An earlier study showed that
COVID-19 patients have substantially higher anti-glycan
antibodies (i.e., IgG and IgM) against self-glycans (e.g., N-
glycans, LacNAc-containing glycans, gangliosides, sialyl Lewis
X, and blood group H), compared to healthy controls (30).
Nevertheless, it is understood that the absence of fucose
increases the capability of IgG to trigger antibody-dependent
cell cytotoxicity (ADCC) via binding to IgG-specific Fc gamma
receptor IIIa (FcgRIIIa) on natural killer (NK) cells, resulting in
the enhancement of inflammatory cytokines produced by
monocytes, including interleukin-1b (IL-1b), IL-6, tumor
necrosis factor-a (TNF-a), C-reactive protein (CRP), and
Interferon-g (IFN-g) (19, 31). This might be the pathway that
IgG afucosylation modulates cytokine storm during the active
phase of the SARS-CoV-2 infection.
IgG sialylation-regulated ADCC plays a role in the pro-
inflammation and anti-inflammation balance in the pathway
similar to fucosylation (32). The absence of sialylation IgG
reduces its efficacy to complement-dependent cytotoxicity
(CDC) activity via C1q binding and leads to an increase in the
activation of the lectin-initiated alternative complement pathway
(24). In this current study, a higher abundance of sialylated
glycans was identified in the COVID-19 group than that in the
controls, reflecting the general features in acute immune
responses (20). Higher levels of bisecting GlcNAc on IgG
enhance ADCC via increased FcgRIII binding and elevate the
proinflammatory function of IgG (33). We found that the total
glycans with bisecting GlcNAc was significantly lower in the
COVID-19 cases than that in the controls. This might cause a
decrease in the modulation of the inflammatory response among
COVID-19 patients, but to a lower degree than that of
fucosylation (11). Agalactosylated IgG is associated with the
activation of the lectin-initiated complement pathway in the
development of inflammatory diseases (34). However, we found
that the levels of agalactosylated glycans were decreased in the
COVID-19 patients.
FIGURE 4 | Galactosylation on IgG in COVID-19 patients and the healthy controls. B, bisecting N-acetylglucosamine (GlcNAc); F, fucose; G, galactose; GP, glycan
peak; S, Sialic acid; ↑, the glycan in COVID-19 group is significantly higher than that in the controls; ↓, the glycan in COVID-19 group is significantly lower than that in
the controls.
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The anti-inflammatory and pro-inflammatory balance related
to pulmonary immunopathology after SARS-CoV-2 infection
might provide a possible explanation for COVID-19 patients
with mild vs. severe clinical phenotypes. Hereby, we compared
the differences of glycan traits between the severe and mild
COVID-19 patients to explore the roles of IgG glycosylation in
the development of SARS-CoV-2 infection between individuals.
Lower levels of sialylated IgG glycans and galactosylated glycans
were observed in the severe patients compared to the mild ones.
These results support earlier findings in the European COVID-
19 patients (18), suggesting that the lectin-initiated alternative
complement pathway modulated by the decreased sialylation
and galactosylation might induce a severe inflammatory process
in severe COVID-19 (11). It was noted that the mild cases (mean
age 42.3 years) are significantly younger than the severe cases
(mean age 57.0 years). Since aging is one of the main factors
inducing the decrease of IgG sialylation and galactosylation (35,
36), the lower levels of sialylation and galactosylation in severe
cases might be partly attributed to a higher age.
Only a small number of patients infected with SARS-CoV-2
develop severe COVID-19, suggesting that there are some
predisposing factors. Although the pre-existing components of
the total IgG pool before SARS-CoV-2 infection are not consistent
with that following the infection, it is hypothesized that the
glycome profile of IgG might be of little variation, especially in
the early stage of infection. Thereby, studies exploring biomarkers
that predict disease association are commonly cross-sectional
studies, which would not allow us to distinguish whether the
reported determinants are pre-existing risk factors (18). Our
follow-up study on the IgG glycosylation profiles proved that
the IgG glycome profiles are stable from the first week of symptom
onset to the fourth week. This makes it predominantly believed
that associations between the IgG glycome composition and
SARS-CoV-2 infection reflect a pre-existing predisposition. Our
finding, in another aspect, validated the previous inference that no
correlation exists between any IgG glycosylations and viral RNA
load during SARS-CoV-2 virus infection (19).
Despite SARS-CoV-2, two coronavirus-induced epidemics have
appeared over the past two decades, including SARS-CoV in 2003
and MERS-CoV in 2012. Researchers have observed an increase in
ADCC activity induced by afucosylated anti-MERS antibodies than
their fucosylated counterparts, which provides a novel perspective
for evaluating the role of the modification of N-glycosylation of the
Fc segment in improving ADCC activity (37). Moreover,
mechanistic experiments demonstrated that during dengue
infection, afucosylated IgG promotes FcgRIIIa signaling, and then
enhances replication of the virus in monocytes (38). In addition,
dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS)
patients respond to infection by producing IgGs with enhanced
affinity for the activating FcgRIIIa due to Fc afucosylation (17).
FIGURE 5 | The hypothesized roles of IgG N-glycosylation in the immunopathology of COVID-19. In COVID-19 cases, afucosylation of IgG Fc segment activates the
antibody-dependent cell mediated cytotoxicity (ADCC) by ligating to FcgRIIIa on natural killer (NK) cells, macrophage, and neutrophil, and then upregulates the
release of proinflammatory factors (e.g., IL-1b, IL-6, CRP, TNF-a, and IFN-g). Among severe cases, agalactosylation and asialylation of IgG upregulates the activation
of the lectin-initiated complement pathway, underlying the complex clinical phenotypes during SARS-CoV-2 infection.
Hou et al. IgG Profile of COVID-19 Patients
Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 7485667
Nearly 45% of individuals infected by SARS-CoV-2 present
asymptomatic (39), but there was little opportunity to enroll such
participants in our study. No asymptomatic cases were enrolled in
our study, which limited the representability of our results. In
addition, anti-viral agents and comorbidities might impact the IgG
glycome profiles. Despite these limitations, we profiled the IgG
glycome in Chinese COVID-19 patients, which contributes to
understanding the immune response to the SARS-CoV-2 infection.
In conclusion, compared to the age- and sex-matched healthy
controls, COVID-19 patients have a decrease in fucosylated IgG,
which upregulates ADCC in acute immune responses. In severe
cases, a low level of IgG sialylation contributes to the
ADCC-regulated enhancement of inflammatory cytokines. The
decreases in sialylation and galactosylation that activate the
lectin-initiated alternative complement pathway also play a
role in COVID-19 pathogenesis, which underlines the complex
clinical phenotypes of the SARS-CoV-2 infection.
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